

We're built around a next-generation technology for bringing critical plasma-derived therapeutics to the people who need them.

People with many rare diseases rely on therapies made from proteins extracted from blood plasma. For more than 75 years, these proteins have been captured through a rudimentary yet expensive process. Until now.

Our patented next-generation technology is the first major advancement in the field since the 1940s. We believe it will help us deliver critical plasma-derived therapeutics at higher levels of purity, efficiency, and quality than conventional methods can.

Ultimately, Evolve aims to improve the lives of people within a largely underserved market—and build future shareholder value in the process.


Our Pipeline

Evolve Biologics is targeting three types of plasma-derived therapeutics. All three types have proven successful in addressing particular conditions.

We aim to commercialize plasma-derived therapeutics using our proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for these products. Evolve is currently in the process of developing a portfolio of product candidates, including IVIG, which is currently in a Phase III clinical trial, Albumin and AAT.

More information about our IVIG trial can be found at clinicaltrials.gov.

Our Process



Our Technology

PlasmaCap EBA[®], Evolve's proprietary and patented technology for protein extraction, plays a key role in our developing portfolio.

Thousands of proteins are found within human blood plasma. Many of these proteins have therapeutic value in treating a range of diseases, including immune deficiencies, autoimmune and neurological disorders, and hemophilia.

Compared to legacy techniques, PlasmaCap EBA is designed to extract more valuable proteins from each liter of donor plasma. This ultimately opens the possibility of helping more people who need them—and doing it more efficiently.

Our Vision

We seek to deliver plasma-derived therapeutics at higher levels of purity, efficiency, and reliability than anyone in our industry.

As a first step toward achieving that vision, we have advanced the technology used to extract plasma proteins from blood. Our patented technique, PlasmaCap EBA[®], is the first major innovation in this area in more than 75 years.

We believe this technique will allow us to advance the quality of plasma-derived therapeutics. It has the potential to extract more value from each liter of precious donor plasma as compared to legacy technology.

And this efficiency drives reliability—in both quality and consistency of supply. Because our technology is proprietary and protected, and we have direct control of our manufacturing, we expect our supply to be more consistent and predictable than today's options.

We think it's about time someone advanced the way biologics are delivered. So Evolve is doing just that.

Contact Us

Location:

Evolve Biologics
420 Ambassador Drive
Mississauga, Ontario, Canada L5T 2J3

General Inquiries:

Please email us at hello@evolvebio.com.

Careers:

Our culture is built on a passion to improve the lives of people with rare diseases. We believe that focus is essential for achieving our vision and providing a workplace where our people can thrive. To inquire about employment with us, email talent@evolvebio.com.

Media Contact:

Gagnier Communications
Jeffrey Mathews / Dan Gagnier at
evolvebio@gagnierfc.com.

Clinical Trials:

Please email Clinical Affairs at
trials@evolvebio.com.



Evolve is a new kind of biologics company.

evolve
biologics